Abstract: A treatment object containing any one of Cu/Ga, Cu/In and Cu—Ga/In is held in a heated state at a temperature T1 for a time ?t1 in such a state that a selenium source is introduced, thereby forming a selenide. Thereafter, a sulfur source is introduced to replace the atmosphere in the system with a sulfur atmosphere. In this state, the treatment object is held in a heated state at a temperature T2 for a time ?t2. The temperature of the treatment object is then decreased to T3, and, at that temperature, the treatment object is held in a heated state for a time ?t3.

Abstract: A treatment object containing any one of Cu/Ga, Cu/In and Cu—Ga/In is held in a heated state at a temperature T1 for a time ?t1 in such a state that a selenium source is introduced, thereby forming a selenide. Thereafter, a sulfur source is introduced to replace the atmosphere in the system with a sulfur atmosphere. In this state, the treatment object is held in a heated state at a temperature T2 for a time ?t2. The temperature of the treatment object is then decreased to T3, and, at that temperature, the treatment object is held in a heated state for a time ?t3.

Abstract: The present invention relates to a pharmaceutical solution comprising the following components (A) and (B): (A) a compound represented by the following formula (1): or a salt thereof, or a hydrate thereof; and (B) a multivalent metal compound, wherein molar ratio of the component (B) to component (A) (the multivalent compound/component (B)) is 0.01 to 0.7. A pharmaceutical solution adapted for intravascular administration containing the quinolone compound at a therapeutically sufficient amount is provided, and this solution exhibits reduced toxicity even when the multivalent metal compound were incorporated at a reduced amount.